MPN Advances Day 2017 | Establishing standardized guidelines on eosinophilia investigation and management in the UK

Name: Establishing standardized guidelines on eosinophilia investigation and management in the UK
Uploaded: 2017-11-17T00:00:00.000Z
Duration: 2 min 50 s

Nauman Butt • 17 Nov 2017

MPN Advances Day 2017

General

Eosinophilia is a highly variable disease that can be relatively mild or potentially fatal; it can occur due to primary or secondary causes, or it can be idiopathic in nature. Because of this variance in its causes and outcomes, there were previously no standardized guidelines for how clinicians should investigate and treat the condition. Speaking from the Myeloproliferative Neoplasms Advances Day 2017 in London, UK, Nauman Butt from the Royal Liverpool and Broadgreen University Hospital NHS Trust, Liverpool, UK, outlines the first UK guidelines for eosinophilia, which he and a group of other UK clinicians published in early 2017.